No increased risk for thrombosis or bleeding seen with concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs.

Patients with lupus nephritis complicated by thrombotic microangiopathy tend to have high death risk and poor renal outcomes. They need vital and effective therapies.

Contemporary donation after circulatory death donors are more medically complex than those from prior eras.

Investigators sought to determine if the gemcitabine intravesical system plus intravenous cetrelimab could improve survival for patients with muscle-invasive bladder cancer who did not receive radical ...